
CSTL Stock Forecast & Price Target
CSTL Analyst Ratings
Bulls say
Castle Biosciences Inc. is experiencing significant growth in its TissueCypher test, with test volume increasing by 92% year-over-year and 23% quarter-over-quarter in the second quarter of 2025, driven by an expanded sales force. The company has also improved the gross margin for the TissueCypher product, achieving an impressive 77% in the most recent quarter, which is anticipated to be supported by a mature gastrointestinal sales force in the second half of 2025. Overall, the strong performance and growth trajectory of the TissueCypher test, along with its industry-leading gross margins, contribute to a positive outlook for Castle Biosciences's stock.
Bears say
Castle Biosciences Inc faces challenges regarding its projected revenue multiples for its dermatology and DecisionDx-UM tests, particularly due to the anticipated lower valuation compared to TissueCypher. The company’s management acknowledged a lack of clinician awareness, especially among gastroenterologists, which could hinder the adoption of their tests, reinforcing concerns about penetration rates in key markets. Despite indications that the stock may appear undervalued based on conservative estimates, the underlying issues related to market awareness and adoption present a negative outlook for future growth and revenue generation.
This aggregate rating is based on analysts' research of Castle Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
CSTL Analyst Forecast & Price Prediction
Start investing in CSTL
Order type
Buy in
Order amount
Est. shares
0 shares